Petros Pharmaceuticals, Inc. (PTPI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1185 Avenue of the Americas
New York City, NY 10036
United States of America (the)
Phone
973-242-0005
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
18
First IPO Date
December 02, 2020
| Name | Title | Pay | Year Born |
| Mitchell S. Arnold | Vice President of Finance & Chief Accounting Officer | 303,523 | 1964 |
| Fady Boctor | President & Chief Commercial Officer | 406,254 | 1978 |
| Joshua N. Silverman | Executive Chairman of the Board | 521,250 | 1970 |
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.